Health News Releases

  • Today April 23
November 03, 2021 13:35
PierianDx Closes up to $47.5 Million of Growth Capital
PierianDx, the global leader in clinical genomics knowledge, announced that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to
November 02, 2021 17:10
ReValve Solutions, Inc. Announces Successful First Human Use of the Transeptal Mitral Valve Replacement
ReValve Solutions, Inc., an innovator in the field of transcatheter structural heart replacement and repair, announced today it has successfully completed the first human use of its transcatheter, Pal
November 02, 2021 16:15
Nathan Jones, CEO of Xlear, Inc. Statement in Response to a Lawsuit Filed by the Department of Justice, on Behalf of the United States, Alleging That Certain Statements Made by Xlear Violated the FTC Act and the Consumer Protection Act
Today, Nathan Jones, CEO of Xlear, Inc. released this statement in response to a lawsuit filed by the Department of Justice, on behalf of the United States, alleging that certain statements made by Xl
November 02, 2021 15:30
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib Study of Its Novel PARP Inhibitor (RP12146) in Patients With Advanced Solid Tumors
Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focused biopharmaceutical company, announced today that it has commenced dosing in a mult
November 02, 2021 14:10
Masimo Launches Dual SET® Pulse Oximetry
Masimo (NASDAQ: MASI) today announced Dual SET® Pulse Oximetry for Root®, a highly versatile patient monitoring and connectivity hub. The first application of Dual SET® Oximetry is a significant advan
November 02, 2021 11:20
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today applied for selection of the “Prime Market” segment of the Tokyo Stock Exchange, Inc. (“TSE”) as its listing market as dete
October 29, 2021 17:10
bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate
Today bit.bio welcomes three new members to its board of directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will
October 29, 2021 17:00
Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis
Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now und
October 29, 2021 11:40
Takeda Announces Acquisition of Own Shares
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of
October 29, 2021 11:30
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2021 (period ended September 30, 2021). Based on the strong f
October 28, 2021 17:40
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiti
October 28, 2021 11:45
Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia
Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announced a new collaboration focused on understanding the malfunctions in brain
October 27, 2021 17:40
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the phase-III trial of Angion’s ANG-3777 did not demonstra
October 27, 2021 16:20
Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: A
October 27, 2021 15:57
Coreline AI Coronary Artery Calcium Solution Shows 99.2% Accuracy From a Population Study
Coreline Soft, the developer of the AI Coronary Artery Calcium (CAC) solution named AVIEW CAC, announced that its AI CAC solution showed 99.2% accuracy from a population study conducted by the Institu
October 27, 2021 09:40
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim and Thoeris GmbH announce a collaboration and license agreement with the aim to investigate novel first-in-class therapies for patients with urea cycle disorders (UCDs). UCDs are
October 26, 2021 16:40
Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis ev
October 22, 2021 16:15
Patient Safety Movement Foundation Welcomes New Leadership
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, today announced Michael A.E. Ramsay, MD, FRC
October 20, 2021 10:40
School of Life Sciences and Technology, Indonesia Wins XVI Fujio Cup Quiz in NCRM NICHE 2021; Rajalakshmi Engineering College, India, Emerge Runners.
Alfred Patisenah and Daisy Ramadhani of School of Life Sciences and Technology, Indonesia, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2021, on s
October 19, 2021 20:05
ANANDA Scientific’s Liquid Structure™ Cannabidiol (CBD) to Be Clinically Evaluated for Opioid Use Disorder
ANANDA Scientific Inc., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery te
October 19, 2021 17:55
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh) and Oxford Bio
October 19, 2021 16:00
Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection and IBD at ACG 2021
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific
October 15, 2021 17:10
New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS
Merck, a leading science and technology company, today shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating that the oral, central nervous system (CNS)-penetrant, fully
October 15, 2021 11:30
Smiths Detection confirms BioFlash detects airborne SARS-CoV-2 variants including Delta and Delta plus
Smiths Detection, a global leader in threat detection and security screening technologies, today confirms that its air sampler, BioFlash®, can detect SARS-CoV-2 variants including the Alpha variant (B
October 14, 2021 17:55
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients
Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company announced today that it has commenced dosing in a phas
25 per page50 per page75 per page100 per page